FDA Approves New Pancreatic Cancer Drug Rasonque

Why it matters locally: The approval of Rasonque could offer a new treatment option for the estimated 1,000 to 1,200 Massachusetts residents diagnosed with pancreatic cancer each year. This new drug may be prescribed by oncologists at major medical centers across the state.

WASHINGTON – The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) today, introducing a new treatment for metastatic pancreatic cancer. Rasonque functions as a RAS inhibitor, targeting the most common form of the disease. Regulators made the approval several months ahead of their projected schedule. The decision makes Rasonque available to patients with advanced pancreatic cancer.